Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Synovial sarcoma

Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors SPEARHEAD-3 Pediatric Study A Study of PRT2527 in Patients With Advanced Solid Tumors A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma 9-ING-41Combined With Chemotherapy in Adolescents and Adults A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Solid Tumors Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients Preoperative Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Bevacizumab and Radiation Therapy for Sarcomas Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Trial of CMB305 and Atezolizumab in Patients With Sarcoma Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Detection of Circulating Tumor Cells in Patients With Sarcomas Sorafenib and Dacarbazine in Soft Tissue Sarcoma MAGE-A4ᶜ¹º³²T for Multi-Tumor NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Synovate Study for Synovial Sarcoma, Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma DHEA in Synovial Sarcoma Patients CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma